Last reviewed · How we verify
Atypical Antipsychotic
At a glance
| Generic name | Atypical Antipsychotic |
|---|---|
| Also known as | olanzapine, quetiapine , ziprasidone and risperidone |
| Sponsor | Dalian Seventh People's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacist-led Interventions in Psychiatric Patients (NA)
- Caplyta in Borderline Personality Disorder (PHASE2)
- The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. (PHASE1)
- Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders. A Double-blind Placebo-controlled Trial. (NA)
- Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial (NA)
- A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication (PHASE3)
- An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication (PHASE3)
- Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atypical Antipsychotic CI brief — competitive landscape report
- Atypical Antipsychotic updates RSS · CI watch RSS
- Dalian Seventh People's Hospital portfolio CI